Clinical Trial News and Research

RSS

New portable system can produce life-saving NO from air by means of electrical spark

Treatment with inhaled nitric oxide (NO) has proven to be life saving in newborns, children and adults with several dangerous conditions, but the availability of the treatment has been limited by the size, weight and complexity of equipment needed to administer the gas and the therapy's high price.

7 Jul 2015

Study could provide paradigm shift in treatment of age-related disease, cancer

Intermittent dosing with rapamycin selectively breaks the cascade of inflammatory events that follow cellular senescence, a phenomena in which cells cease to divide in response to DNA damaging agents, including many chemotherapies.

7 Jul 2015

Transitioning Infrared Imaging into Clinical Use

The CLIRSPEC network is a UK Engineering and Physical Sciences Research Council (EPSRC – EP/L012952/1) funded network in clinical infrared and Raman spectroscopy. Infrared and Raman spectroscopy can identify the hallmarks of disease and distinguish between diseased and non-diseased samples based upon inherent chemistry.

From Daylight Solutions Inc 7 Jul 2015

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.

7 Jul 2015

Breakthrough discovery could help young girls suffering from rare form of epilepsy

An international team, led by a University of Adelaide genetics expert, has made a breakthrough discovery which is expected to help thousands of young girls worldwide who are suffering from a rare yet debilitating form of epilepsy.

7 Jul 2015

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US.

7 Jul 2015

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen (ISIS-APOCIIIRx) for the treatment of patients with Familial Chylomicronemia Syndrome (FCS).

6 Jul 2015

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies.

6 Jul 2015

UTHealth School of Public Health working to improve health of Hispanics living along Texas-Mexico border

Sylvia Hernando became a Community Health Worker (CHW) because she wanted to help others. Hernando had been a stay-at-home mother and was looking to go back to school when she heard about the CHW certification program at The University of Texas Health Science Center at Houston School of Public Health.

6 Jul 2015

Boehringer Ingelheim’s Spiolto Respimat approved for COPD treatment in first European countries

Boehringer Ingelheim today announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in first European countries. Spiolto Respimat is a once-daily maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

3 Jul 2015

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Working in cell cultures and mice, researchers at Johns Hopkins have found that an experimental drug called fostamatinib combined with the chemotherapy drug paclitaxel may overcome ovarian cancer cells' resistance to paclitaxel.

2 Jul 2015

Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

Galderma, a global healthcare company focused on skin health, announced today that it has received U.S. Food and Drug Administration approval to market Restylane Lyft for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21.

2 Jul 2015

New NEI study shows that microglia can accelerate damage wrought by blinding eye disorders

Spider-like cells inside the brain, spinal cord and eye hunt for invaders, capturing and then devouring them. These cells, called microglia, often play a beneficial role by helping to clear trash and protect the central nervous system against infection. But a new study by researchers at the National Eye Institute (NEI) shows that they also accelerate damage wrought by blinding eye disorders, such as retinitis pigmentosa.

2 Jul 2015

24% rise in the number of clinical trials according to Cell Therapy Catapult annual UK analysis

The Cell Therapy Catapult has published its annual analysis of the UK preclinical and clinical research landscapes with the release of its UK Clinical and Pre-Clinical Trials Databases. These show a 24% rise in the number of clinical trials and an increase of 22% in the number of pre-clinical projects. Sector growth came in the key areas of oncology, neurology, ophthalmology and cardiovascular.

2 Jul 2015

New article highlights learnings gleaned from monitoring complex HIV clinical trials in Africa

A new article in Clinical Investigation highlights the learnings gleaned from monitoring several complex HIV clinical trials in Africa over a 15 year period.

2 Jul 2015

Use of antipsychotic drugs more common in boys than girls, research shows

Boys are more likely than girls to receive a prescription for antipsychotic medication regardless of age, researchers have found.

2 Jul 2015

Researchers complete phase 1 clinical trial of new drug for children suffering from neuroblastoma

Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, MD, pediatric oncologist at Helen DeVos Children's Hospital and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients.

2 Jul 2015

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health's California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS Association for $1.5 million to help fund a Phase 2 clinical study of the company's investigational therapy for ALS, NP001.

1 Jul 2015

Nuclea and Aelan partner to develop, commercialize novel biomarker tests using STEM cells as models

Nuclea Biotechnologies Inc. announced today that it is partnering with Aelan Cell Technologies Inc. (San Francisco, California) for the development, validation and commercialization of novel biomarker tests and companion diagnostics using human STEM cells as models.

1 Jul 2015

FAU awarded $2.1 million to examine effectiveness of antipsychotic medication for schizophrenia

Florida Atlantic University's Charles E. Schmidt College of Medicine was recently awarded a $2.1 million, two-year contract by Otsuka America Pharmaceutical Inc. to conduct a study to examine the effectiveness of an injectable long-acting antipsychotic medication for schizophrenia and its impact on 30-day hospital readmission rates.

1 Jul 2015

Clinical Trial News and Research

New portable system can produce life-saving NO from air by means of electrical spark

Study could provide paradigm shift in treatment of age-related disease, cancer

Transitioning Infrared Imaging into Clinical Use

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

Breakthrough discovery could help young girls suffering from rare form of epilepsy

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

UTHealth School of Public Health working to improve health of Hispanics living along Texas-Mexico border

Boehringer Ingelheim’s Spiolto Respimat approved for COPD treatment in first European countries

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Galderma obtains FDA approval for Restylane Lyft to restore structure to the cheeks and midface area

New NEI study shows that microglia can accelerate damage wrought by blinding eye disorders

24% rise in the number of clinical trials according to Cell Therapy Catapult annual UK analysis

New article highlights learnings gleaned from monitoring complex HIV clinical trials in Africa

Use of antipsychotic drugs more common in boys than girls, research shows

Researchers complete phase 1 clinical trial of new drug for children suffering from neuroblastoma

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Nuclea and Aelan partner to develop, commercialize novel biomarker tests using STEM cells as models

FAU awarded $2.1 million to examine effectiveness of antipsychotic medication for schizophrenia

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer